Search hospitals > New York > New York
Memorial Sloan Kettering Cancer Center
Claim this profileNew York, New York 10065
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Solid Tumors
Conducts research for Pancreatic Cancer
4169 reported clinical trials
427 medical researchers
Summary
Memorial Sloan Kettering Cancer Center is a medical facility located in New York, New York. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Solid Tumors, Pancreatic Cancer and other specialties. Memorial Sloan Kettering Cancer Center is involved with conducting 4,169 clinical trials across 1,795 conditions. There are 427 research doctors associated with this hospital, such as Christopher J. Forlenza, Thomas Kaley, MD, Nancy Lee, MD, and Andrea Cercek, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Breast Cancer
Global LeaderStage IV
Stage III
HER2 negative
Top PIs
Christopher J. ForlenzaMemorial Sloan Kettering Cancer Center8 years of reported clinical research
Expert in Langerhans Cell Histiocytosis
Expert in Neuroblastoma
18 reported clinical trials
38 drugs studied
Thomas Kaley, MDMemorial Sloan Kettering Cancer Center7 years of reported clinical research
Expert in Brain Tumor
Studies Glioblastoma
15 reported clinical trials
23 drugs studied
Nancy Lee, MDMemorial Sloan Kettering Cancer Center2 years of reported clinical research
Studies Neck Cancer
Studies Squamous Cell Carcinoma
14 reported clinical trials
31 drugs studied
Andrea Cercek, MDMemorial Sloan Kettering Cancer Center2 years of reported clinical research
Studies Colorectal Cancer
Studies Rectal Cancer
15 reported clinical trials
32 drugs studied
Clinical Trials running at Memorial Sloan Kettering Cancer Center
Lung Cancer
Breast Cancer
Skin Cancer
Cancer
Brain Tumor
Ovarian Cancer
Breast cancer
Cervical Cancer
Testicular cancer
Bladder Cancer
Radiation Therapy
for Brain Metastasis
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.
Recruiting2 awards Phase 312 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Proton Craniospinal Radiation
for Cancer in the Brain and Spinal Cord
This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal fluid filled space that surrounds the brain and spinal cord (leptomeningeal metastasis). Patients with leptomeningeal metastasis (LM) may develop multiple areas of nervous system (neurologic) impairment that can be life-threatening. Radiation therapy (RT) effectively relieves local symptoms due to LM. RT uses high energy radiography (x-rays), particles, or radioactive seeds to kill cancer cells and shrink tumors. IFRT is commonly used to treat symptoms of LM. IFRT is radiation treatment that uses x-rays to treat specific areas of LM and to relieve and/or prevent symptoms. pCSI uses protons that can be directed with more accuracy than x-rays which allows treatment of the entire central nervous system space containing the cerebrospinal fluid (CSF), brain, and spinal cord. The pCSI treatment could delay the worsening of LM. Giving pCSI may be better than IFRT in treating LM in patients with breast or non-small cell lung cancer.
Recruiting2 awards Phase 33 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Memorial Sloan Kettering Cancer Center?
Memorial Sloan Kettering Cancer Center is a medical facility located in New York, New York. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Solid Tumors, Pancreatic Cancer and other specialties. Memorial Sloan Kettering Cancer Center is involved with conducting 4,169 clinical trials across 1,795 conditions. There are 427 research doctors associated with this hospital, such as Christopher J. Forlenza, Thomas Kaley, MD, Nancy Lee, MD, and Andrea Cercek, MD.
Where is Memorial Sloan Kettering Cancer Center located?
Memorial Sloan Kettering Cancer Center is situated at 1275 York Avenue, New York, NY, nestled between 67th and 68th streets. For the main entrance, head south on York Avenue and make a right turn onto East 66th Street. The parking garage is conveniently located a quarter block from the corner, on the right side of 66th Street.
Who should I call to ask about financial aid or insurance network?
Memorial Sloan Kettering Cancer Center (MSK) offers comprehensive support for patients, including:
- **Insurance Assistance**: For queries, contact 800-525-2225.
- **Financial Assistance Program (FAP)**: Helps manage treatment costs based on income and assets. Apply by calling 646-227-3378.
- **Prescription Assistance**: Aids patients with high medication co-pays.
- **Social Worker Support**: Offers emotional support and practical assistance, including transportation and financial issues.
What insurance does Memorial Sloan Kettering Cancer Center accept?
Memorial Sloan Kettering Cancer Center (MSK) accepts various insurance plans, including Medicare and Medicaid. Patients are responsible for co-insurance, deductible costs for Medicare, and co-payments for Medicaid. MSK has relationships with many insurance providers, including Aetna, Blue Cross Blue Shield, Cigna, and UnitedHealthcare, among others. For specific plan participation and financial assistance options, please contact MSK directly. For insurance inquiries, call 646-497-9176; for billing questions, call 646-227-3378, Monday through Friday.
What awards or recognition has Memorial Sloan Kettering Cancer Center received?
Memorial Sloan Kettering Cancer Center (MSK) is renowned for its groundbreaking research and exceptional care, leading over 900 clinical trials aimed at enhancing treatment for adult and pediatric cancers. From 1980 to 2015, the US Food and Drug Administration approved ten drugs developed by MSK, showcasing an unmatched success rate among cancer centers. Additionally, MSK scientists have earned national and international accolades for their pioneering contributions to science and medicine.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.